Centre Proposes Immediate Suspension of Licences for Manufacturers of Substandard Drugs

NEW DELHI, Nov 5: The Union Ministry of Health and Family Welfare has proposed stricter regulations to prevent the manufacturing and distribution of substandard medicines, introducing a provision for the immediate suspension of manufacturing licences when drugs fail to meet specified critical quality standards.

The proposed amendments to the Drugs Rules, 1945, are aimed at strengthening pharmaceutical regulation, improving accountability among drug manufacturers and ensuring that medicines available to patients meet prescribed safety and quality requirements.

Under the proposed changes, the Central Licensing Approving Authority or the concerned State Licensing Authority would be empowered to immediately suspend the manufacturing licence of a drug upon receiving a Government Analyst’s report declaring it Not of Standard Quality (NSQ) on specified parameters.

These parameters include assay, dissolution, related substances, impurities and sterility. The government considers these factors essential for determining whether a medicine meets the required quality standards and is suitable for use.

The proposed action is intended to address a gap in the existing regulatory framework, under which suspension or cancellation of a manufacturing licence generally involves a prescribed procedure, including the issuance of a show-cause notice.

The Health Ministry has pointed out that the existing process can create a delay between identifying a drug as substandard and taking regulatory action. During this period, the concerned medicine may continue to remain in circulation, potentially exposing patients to avoidable health risks and making an effective recall more difficult.

The proposed provision seeks to enable authorities to intervene without waiting for the completion of the usual preliminary process when serious quality deficiencies are identified.

Corrective action made mandatory

The draft amendments also establish conditions that manufacturers would have to fulfil before a suspended licence could be restored.

According to the proposed framework, the suspension would remain in force until the manufacturer conducts a comprehensive Root Cause Analysis to determine why the medicine failed to meet the prescribed standards.

The manufacturer would subsequently be required to introduce appropriate Corrective and Preventive Actions (CAPA) to address the identified shortcomings and prevent similar failures in future production.

The concerned licensing authority would examine the corrective measures and verify their implementation before permitting the suspension to be revoked.

This provision is intended to ensure that manufacturers do not resume operations merely by submitting explanations or assurances. Instead, they would have to demonstrate that the underlying quality-related problems have been identified and adequately addressed.

The approach also places greater responsibility on pharmaceutical companies to maintain consistent quality-control systems throughout the manufacturing process.

Stronger coordination among drug regulators

The Ministry has also proposed changes to Form 13, which relates to the test report issued by a Government Analyst.

Under the proposed arrangement, the report identifying a medicine as Not of Standard Quality would be shared with the Drugs Controller General of India (DCGI), the relevant State or Union Territory licensing authority, and the manufacturer and marketer of the concerned medicine.

The proposed reporting mechanism is expected to improve communication between regulatory authorities and pharmaceutical companies, allowing relevant agencies to initiate timely action after receiving information about quality failures.

It would also help ensure that the concerned manufacturer and marketer are formally informed about deficiencies detected during testing.

Coordination between central and state authorities is particularly important because pharmaceutical manufacturing and distribution involve multiple regulatory jurisdictions. A medicine manufactured in one state may be marketed and distributed across several other parts of the country.

Consequently, timely sharing of laboratory findings can help authorities coordinate their response and assess whether additional regulatory measures are required.

Background of the proposed amendments

The latest proposal follows discussions held at the 65th meeting of the Drugs Consultative Committee on December 20, 2024, and recommendations made during the 92nd meeting of the Drugs Technical Advisory Board on April 24, 2025.

These consultations formed part of the government’s broader efforts to strengthen the regulatory framework governing pharmaceutical manufacturing and ensure better compliance with prescribed quality standards.

India has a substantial pharmaceutical manufacturing sector, supplying medicines to domestic consumers as well as international markets. Maintaining the quality of medicines is therefore important not only for public health but also for the credibility of the country’s pharmaceutical industry.

The quality of a medicine depends on several factors, including the accuracy of its active ingredients, the consistency of its formulation, its ability to dissolve appropriately and the absence of harmful contamination.

A failure in any of these areas can affect the medicine’s intended performance and may create risks for patients.

For instance, assay testing determines whether a medicine contains the required amount of active pharmaceutical ingredients. Dissolution testing assesses how the drug releases its active ingredients under specified conditions.

Similarly, testing for impurities and related substances helps identify unwanted chemical components, while sterility testing is particularly important for medicines that must be free from viable microorganisms.

The proposed amendments specifically identify these parameters as grounds for immediate regulatory intervention.

Public consultation before final notification

The Ministry has invited objections and suggestions from pharmaceutical industry representatives, stakeholders and members of the public on the draft amendments.

Interested parties have been given 30 days from the date the relevant Gazette notification becomes available to submit their comments and recommendations.

The ministry has indicated that feedback can be submitted to the Under Secretary (Drugs), Ministry of Health and Family Welfare, at Kartavya Bhawan-1, New Delhi, or through the designated official email address.

The consultation process will allow stakeholders to examine the proposed provisions and communicate concerns or suggestions before the amendments are finalised.

The proposal does not mean that the new suspension mechanism has already come into force. It remains a draft regulatory measure until the prescribed consultation and notification process is completed.

Implications for pharmaceutical manufacturers

If implemented, the proposed changes could require manufacturers to strengthen their internal quality-assurance systems and ensure that problems identified during production are addressed before medicines reach the market.

Companies may also need to improve documentation, laboratory testing procedures and coordination between their manufacturing, quality-control and regulatory compliance departments.

The possibility of immediate suspension could increase the importance of identifying quality-related problems at an early stage rather than relying primarily on inspections conducted after products have entered distribution channels.

For smaller manufacturers, maintaining adequate testing infrastructure and qualified technical personnel may become increasingly important. Larger companies would also need to ensure that their quality-management systems operate consistently across manufacturing facilities.

The proposal could additionally encourage pharmaceutical companies to review their existing procedures for handling failed batches, investigating deviations and implementing preventive measures.

However, effective implementation will depend on the capacity of regulatory authorities to conduct reliable testing, communicate findings promptly and verify corrective measures objectively.

Patient safety remains central

The proposed amendments place patient safety at the centre of pharmaceutical regulation by seeking to reduce the time between identifying a serious quality failure and taking action against the concerned manufacturing licence.

For patients, the quality of medicines is an essential part of healthcare. Treatment outcomes depend not only on receiving the correct prescription but also on the safety, effectiveness and reliability of the medicines being supplied.

The proposed mechanism is intended to strengthen confidence in the pharmaceutical supply chain by making regulatory intervention faster and establishing clearer accountability for quality failures.

As the government moves ahead with the consultation process, the feedback received from manufacturers, medical professionals and other stakeholders will be important in shaping the final regulatory framework.

The proposed changes represent another step towards strengthening oversight of India’s pharmaceutical industry and ensuring that medicines manufactured and marketed in the country comply with established quality requirements.